Skyscape Web Viewer : Cancer Pharmacology: An Illustrated Manual of Anticancer Drugs : Main Index

View All
dacarbazine (DTIC) Alkylating Agents Triazines (Three Attached Nitrogen Atoms)
DAMPA
DCK
DDB1
dehydroepiand rosterone (DHEA)
de novo synthesis of thymidine monophosphate (dTMP)
deoxycytidine triphosphate (dCTP)
deoxynucleotide triphosphates (dNTPs) Ribonucleotide Reductase (RNR) is Responsible for Synthesizing Deoxyribonucleotides Answer 3.7
deoxythymidine monophosphate (dTMP) Mechanism of Leucovorin (LV) "Rescue" in High-Dose Methotrexate (MTX) Folic Acid Cycle as Relevant for Conversion of Deoxyuridine Monophosphate (dUMP) Pyrimidine Analogs
deoxyuridine monophosphate (dUMP)
DFS
DHF
differentiation syndrome (DS) Answer 8.2 Question 8.2 Differentiating Agents and Microenvironment
dihydrofolate (DHF)
dihydrofolate reductase (DFHR) Antimetabolites: Hydroxyurea, Pyrimidine and Purine Analogs, and L-Asparaginase Answer 3.7 Question 4.5
dihydrotestosterone (DHT)
disease-free survival (DFS) Basic Drug Development With Structural Considerations Answer 16.5
DNA binding protein 1 (DDB1)
DNA damage response (DRR) DNA Repair, Apoptotic Pathways, CDK Inhibitors DNA-PK targeting PARP inhibitors
DNA methyltransferase (DNMT)
DNA repair risk and intensity overview
DNMT
docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)
dose-limiting toxicity (DLT)
DRESS
Drug approval and regulatory issues additional pharmacology considerations drug-drug interaction hepatic impairment QT prolongation renal impairment dose refinement studies food effect INDâchr(128)”enabling nonclinical studies for cancer drugs recommended phase 2 dose (RP2D)
Drug developments clinical trial facts and phases overview protocols clinical trial definitions new active substance launches from 2011 to 2016 by indication patient selection and study design RECIST 1.1, the WHO, and the irRC Criteria
drug reaction with eosinophilia and systemic symptoms (DRESS) Answer 14.2 Question 14.2
DS
dTNP. see deoxyribonucleotide triphosphates (dTNP)